Abstract
The peripheral anionic site of acetylcholinesterase lies at the entrance to the active site gorge. It is composed of five residues (Tyr 70, Asp 72, Tyr 121, Trp 279 and Tyr 334; Torpedo numbering); associated with it are a number of surface loops, conferring a high degree of conformational flexibility on the area. The site is involved in the allosteric modulation of catalysis at the active centre and is the target of various anti-cholinesterases. It is also implicated in a number of non-classical functions, in particular, amyloid deposition, cell adhesion and neurite outgrowth. A number of peptide and protein ligands for the site have been identified. In this review, the structure and multiple functions of the peripheral anionic site are discussed, together with its potential as a target in rational drug design for the development of novel and improved inhibitors and of therapeutics for the treatment of neural cancers, nerve regeneration and neurodegenerative disorders such as Alzheimers disease.
Keywords: Acetylcholinesterase, peripheral anionic site, allosterism, inhibitors, non-cholinergic, rational drug design
Current Pharmaceutical Design
Title: The Peripheral Anionic Site of Acetylcholinesterase: Structure, Functions and Potential Role in Rational Drug Design
Volume: 12 Issue: 2
Author(s): G. Johnson and S. W. Moore
Affiliation:
Keywords: Acetylcholinesterase, peripheral anionic site, allosterism, inhibitors, non-cholinergic, rational drug design
Abstract: The peripheral anionic site of acetylcholinesterase lies at the entrance to the active site gorge. It is composed of five residues (Tyr 70, Asp 72, Tyr 121, Trp 279 and Tyr 334; Torpedo numbering); associated with it are a number of surface loops, conferring a high degree of conformational flexibility on the area. The site is involved in the allosteric modulation of catalysis at the active centre and is the target of various anti-cholinesterases. It is also implicated in a number of non-classical functions, in particular, amyloid deposition, cell adhesion and neurite outgrowth. A number of peptide and protein ligands for the site have been identified. In this review, the structure and multiple functions of the peripheral anionic site are discussed, together with its potential as a target in rational drug design for the development of novel and improved inhibitors and of therapeutics for the treatment of neural cancers, nerve regeneration and neurodegenerative disorders such as Alzheimers disease.
Export Options
About this article
Cite this article as:
Johnson G. and Moore W. S., The Peripheral Anionic Site of Acetylcholinesterase: Structure, Functions and Potential Role in Rational Drug Design, Current Pharmaceutical Design 2006; 12 (2) . https://dx.doi.org/10.2174/138161206775193127
DOI https://dx.doi.org/10.2174/138161206775193127 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Multidisciplinary Pharmaceutical Drug Design Strategies in the Progress of Drug Discovery"
The process of developing a drug is time- and money-consuming, but also fascinating. The development of numerous computational techniques, synthetic methodologies, formulation-based drug discovery, etc. has improved the drug discovery process. The process of developing new drugs is significantly hampered by drug-poor pharmacodynamics and pharmacokinetic problems. To address these challenges, ...read more
Advances in the Molecular Pathogenesis of Inflammatory Bowel Disease.
This thematic issue will emphasize the recent breakthroughs in the mechanisms of Inflammatory bowel disease (IBD) pathogenesis and devotes some understanding of both Crohn’s and ulcerative colitis. It is expected to include studies about cellular and genetic aspects, which help to precipitate the disease, and the immune system-gut microbiome relations ...read more
Blood-based biomarkers in large-scale screening for neurodegenerative diseases
Disease biomarkers are necessary tools that can be employed in several clinical context of use (COU), ranging from the (early) diagnosis, prognosis, and prediction, to monitoring of disease state and/or drug efficacy. Regarding neurodegenerative diseases, in particular Alzheimer’s disease (AD), a battery of well-validated biomarkers are available, such as cerebrospinal ...read more
Diabetes mellitus: advances in diagnosis and treatment driving by precision medicine
Diabetes mellitus (DM) is a chronic degenerative metabolic disease with ever increasing prevalence worldwide which is now an epidemic disease affecting 500 million people worldwide. Insufficient insulin secretion from pancreatic β cells unable to maintain blood glucose homeostasis is the main feature of this disease. Multifactorial and complex nature of ...read more

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Erythrocyte Associated Amyloid-β as Potential Biomarker to Diagnose Dementia
Current Alzheimer Research Recent Advances on Type-2 Cannabinoid (CB<sub>2</sub>) Receptor Agonists and their Therapeutic Potential
Current Medicinal Chemistry Poly(ADP-Ribose) Polymerase Inhibitors: New Pharmacological Functions and Potential Clinical Implications
Current Pharmaceutical Design The gp130 Receptor Cytokine Family: Regulators of Adipocyte Development and Function
Current Pharmaceutical Design Patent Selections
Recent Patents on CNS Drug Discovery (Discontinued) Mild Parkinsonian Signs in a Hospital-based Cohort of Mild Cognitive Impairment Types: A Cross-sectional Study
Current Alzheimer Research Development of Calorie Restriction Mimetics as Therapeutics for Obesity, Diabetes, Inflammatory and Neurodegenerative Diseases
Current Genomics Nucleic Acid Aptamers as Novel Class of Therapeutics to Mitigate Alzheimer’s Disease Pathology
Current Alzheimer Research The Hypocretins and their Role in Narcolepsy
CNS & Neurological Disorders - Drug Targets Antagonists of IAP Proteins: Novel Anti-Tumor Agents
Current Medicinal Chemistry Tryptophan Catabolites and Their Impact on Multiple Sclerosis Progression
Current Pharmaceutical Design Circulating Advanced Oxidation Protein Products as Oxidative Stress Biomarkers and Progression Mediators in Pathological Conditions Related to Inflammation and Immune Dysregulation
Current Medicinal Chemistry Berberine: A Plant-derived Alkaloid with Therapeutic Potential to Combat Alzheimer’s disease
Central Nervous System Agents in Medicinal Chemistry Molecular Targets of Tannic Acid in Alzheimer's Disease
Current Alzheimer Research Plausible Improvements for Selective Targeting of Dopamine Receptors in Therapy of Parkinson’s Disease
Mini-Reviews in Medicinal Chemistry Epigenetic Multiple Modulators
Current Topics in Medicinal Chemistry The Role of Lipid Nanoparticles and its Surface Modification in Reaching the Brain: An Approach for Neurodegenerative Diseases Treatment
Current Drug Delivery Microglia and Astrocytes in Alzheimer's Disease: Implications for Therapy
Current Neuropharmacology Glutamate in CNS Neurodegeneration and Cognition and its Regulation by GCPII Inhibition
Current Medicinal Chemistry Hazelnut Modulates Neurobehaviour and Ameliorates Ageing-induced Oxidative Stress, and Caspase-3-Mediated Apoptosis in Mice
Current Aging Science